Want to see SI full AI Analyst Report?
SI Stock Chart & Stats
$20.41
$0.55(2.69%)
At close: 4:00 PM EDT
$20.41
$0.55(2.69%)
Day’s Range― - ―
52-Week Range$10.92 - $24.60
Previous Close$15.29
Volume51.57K
Average Volume (3M)130.31K
Market Cap
$408.68M
Enterprise Value$336.38
Total Cash (Recent Filing)$98.99M
Total Debt (Recent Filing)$14.85M
Price to Earnings (P/E)―
Beta-0.46
Next Earnings
Nov 17, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding20,818,956
10 Day Avg. Volume85,080
30 Day Avg. Volume130,306
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.90
Price to Sales (P/S)6.23
P/FCF Ratio-8.19
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$24.75Price Target Upside21.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.71
Revenue Forecast (FY)$67.28M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And Surgeon AdoptionRapid, repeatable adoption by surgeons and accelerating implant volume indicate true commercial traction in an underpenetrated shoulder market. Durable top-line momentum across channels supports scaling revenue as new customers convert and utilization deepens, giving a multi-quarter runway for sustained growth.
High And Improving Gross MarginsConsistently high gross margins reflect attractive unit economics and pricing power for implant products. Sustained ~77% gross profitability provides structural cushion to fund SG&A and R&D investments while offering a credible pathway to eventual operating leverage as revenue scales.
Differentiated Product Pipeline And Robotic PartnershipProduct launches, clinical registry scale and a progressing robotic partnership are structural competitive assets. Regulatory progress and new indications expand addressable market and create stickiness with surgeons, increasing long-term differentiation and potential to capture higher ASPs and utilization.
Bears Say
Accelerating Negative Operating And Free Cash FlowPersistent, sizable cash burn increases reliance on external capital and elevates funding risk if markets tighten. Negative operating and free cash flow mean current operations do not self-fund growth, pressuring runway and forcing prioritization between scale investments and liquidity preservation over coming quarters.
Widening Operating Losses And Rising Operating SpendOperating expense growth outpacing revenue creates sustained negative margins despite top-line strength. Prolonged elevated SG&A and R&D to scale commercial footprint and develop tech may delay path to profitability and depress returns, making margin recovery dependent on disciplined cost control as revenue scales.
Balance Sheet Being Used To Fund Operating DeficitsLow leverage gives flexibility, but rising equity and assets are financing ongoing losses rather than compounding shareholder value. Continued negative returns risk diluting long-term ROE and could force future capital raises or constrained investment choices if operating performance doesn't improve.
Shoulder Innovations, Inc. News
SI FAQ
What was Shoulder Innovations, Inc.’s price range in the past 12 months?
Shoulder Innovations, Inc. lowest stock price was $10.92 and its highest was $24.59 in the past 12 months.
What is Shoulder Innovations, Inc.’s market cap?
Shoulder Innovations, Inc.’s market cap is $408.68M.
When is Shoulder Innovations, Inc.’s upcoming earnings report date?
Shoulder Innovations, Inc.’s upcoming earnings report date is Nov 17, 2026 which is in 96 days.
How were Shoulder Innovations, Inc.’s earnings last quarter?
Shoulder Innovations, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.459 by -$0.031.
Is Shoulder Innovations, Inc. overvalued?
According to Wall Street analysts Shoulder Innovations, Inc.’s price is currently Undervalued.
Does Shoulder Innovations, Inc. pay dividends?
Shoulder Innovations, Inc. does not currently pay dividends.
What is Shoulder Innovations, Inc.’s EPS estimate?
Shoulder Innovations, Inc.’s EPS estimate is -0.51.
How many shares outstanding does Shoulder Innovations, Inc. have?
Shoulder Innovations, Inc. has 20,818,956 shares outstanding.
What happened to Shoulder Innovations, Inc.’s price movement after its last earnings report?
Shoulder Innovations, Inc. reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.459. Following the earnings report the stock price went down -8.203%.
Which hedge fund is a major shareholder of Shoulder Innovations, Inc.?
Currently, no hedge funds are holding shares in SI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shoulder Innovations, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.75 (21.26% Upside)
$24.75 (21.26% Upside)
Blogger Sentiment
Bearish
SI Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 482.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
95.31%
Trailing 12-Months
Company Description
Shoulder Innovations, Inc.
Shoulder Innovations, Inc. manufactures medical devices. It has developed a shoulder replacement system. The company was founded by Stephen B. Gunther and Michael DeVries in 2009 and is headquartered in Grand Rapids, MI.
SI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong operating and commercial momentum: sizable revenue and volume growth, improving gross margins, accelerating surgeon adoption and meaningful product and technology milestones (I-135 full launch, N22 limited release, >500 patients in registry, and a progressing robotic partnership). These positives were offset by increased operating expenses and larger net and adjusted EBITDA losses as the company invests to scale, a Q1 cash burn driven by inventory and working capital, and some seasonality and ASP/mix variability risk embedded in the updated guidance. Overall, management expressed high conviction in the trajectory and raised full-year guidance while noting near-term investment-related impacts.View all SI earnings summariesSI Stock 12 Month Forecast
Average Price Target
$24.75
▲(21.26% Upside)
Technical Analysis
Ownership Overview
28.11% Insiders
14.10% Mutual Funds
4.38% Other Institutional Investors
49.16% Public Companies and
Individual Investors